| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rutin, a Quercetin Glycoside Rutin, a natural flavonoid glycoside found in many plants like buckwheat, citrus fruits, and apples, has shown promising neuroprotective and anticancer properties. Rutin is a flavonoid glycoside composed of quercetin bound to the disaccharide rutinose. It is widely found in buckwheat, citrus fruits, apples, and tea. In cancer models, rutin exhibits antioxidant, anti-inflammatory, anti-proliferative, and pro-apoptotic effects. Because it is glycosylated, rutin itself has relatively low cellular permeability; many biological effects are mediated after intestinal hydrolysis to quercetin and subsequent phase-II metabolites. Mechanistically, rutin is most consistently associated with suppression of NF-κB and PI3K/AKT signaling, modulation of MAPK pathways, redox regulation (Nrf2/ROS balance), inhibition of angiogenesis (VEGF), and induction of cell-cycle arrest and apoptosis in preclinical systems. Effects are model-dependent and often concentration-dependent, with antioxidant behavior dominating in normal tissue contexts and context-dependent pro-oxidant effects described in some tumor settings. -Scavenges free radicals, reduces oxidative stress -Inhibits pro-inflammatory cytokines like IL-1β, TNF-α, and reduces activation of NF-κB. -Inhibition of Aβ Aggregation (AD) -Mild inhibitory effects on acetylcholinesterase (AChE), helping enhance cholinergic function. -May upregulate BDNF expression Cancer: -Induces cell cycle arrest in G2/M phase. -Inhibits VEGF, Suppresses MMP-2 and MMP-9 -Inhibits PI3K/Akt/mTOR, MAPK, and NF-κB signaling pathways. -Enhances sensitivity to Chemotherapy drugs like doxorubicin and cisplatin Rutin has poor oral bioavailability, but this can be improved with nanoformulations or co-administration with absorption enhancers like piperine or quercetin. Cancer Pathway Table: Rutin
TSF: P = 0–30 min (rapid redox interactions), R = 30 min–3 hr (acute signaling shifts), G = >3 hr (gene-regulatory adaptation and phenotype outcomes).
Alzheimer’s Disease (AD) Summary — RutinRutin has been studied in preclinical neurodegeneration models for its antioxidant, anti-inflammatory, and mitochondrial-protective properties. It is reported to modulate Nrf2 signaling, suppress NF-κB–mediated neuroinflammation, reduce oxidative stress, and attenuate amyloid-β–induced neuronal injury in experimental systems. Many effects may be mediated after hydrolysis to quercetin. Human clinical evidence remains limited.Alzheimer’s Disease Table: Rutin
TSF: P = 0–30 min (early signaling modulation), R = 30 min–3 hr (stress-response shifts), G = >3 hr (gene-regulatory and neuroprotective outcomes). |
| Source: |
| Type: |
| Oxidative phosphorylation (or phosphorylation) is the fourth and final step in cellular respiration. Alterations in phosphorylation pathways result in serious outcomes in cancer. Many signalling pathways including Tyrosine kinase, MAP kinase, Cadherin-catenin complex, Cyclin-dependent kinase etc. are major players of the cell cycle and deregulation in their phosphorylation-dephosphorylation cascade has been shown to be manifested in the form of various types of cancers. Many tumors exhibit a well-known metabolic shift known as the Warburg effect, where glycolysis is favored over OxPhos even in the presence of oxygen. However, this is not universal. Many cancers, including certain subpopulations like cancer stem cells, still rely on OXPHOS for energy production, biosynthesis, and survival. – In several cancers, especially during metastasis or in tumors with high metabolic plasticity, OxPhos can remain active or even be upregulated to meet energy demands. In some cancers, high OxPhos activity correlates with aggressive features, resistance to standard therapies, and poor outcomes, particularly when tumor cells exploit mitochondrial metabolism for survival and metastasis. – Conversely, low OxPhos activity can be associated with a reliance on glycolysis, which is also linked with rapid tumor growth and certain adverse prognostic features. Inhibiting oxidative phosphorylation is not a universal strategy against all cancers. Targeting OXPHOS can potentially disrupt the metabolic flexibility of cancer cells, leading to their death or making them more susceptible to other treatments. Since normal cells also rely on OXPHOS, inhibitors must be carefully targeted to avoid significant toxicity to healthy tissues. Not all tumors are the same. Some may be more glycolytic, while others depend more on mitochondrial metabolism. Therefore, metabolic profiling of tumors is crucial before adopting this strategy. Inhibiting OXPHOS is being explored in combination with other treatments (such as chemo- or immunotherapies) to improve efficacy and overcome resistance. In cancer cells, metabolic reprogramming is a hallmark where cells often rely on glycolysis (known as the Warburg effect); however, many cancer types also depend on OXPHOS for energy production and survival. Targeting OXPHOS(using inhibitor) to increase the production of reactive oxygen species (ROS) can selectively induce oxidative stress and cell death in cancer cells. -One side effect of increased OXPHOS is the production of reactive oxygen species (ROS). -Many cancer cells therefore simultaneously upregulate antioxidant systems to mitigate the damaging effects of elevated ROS. -Increase in oxidative phosphorylation can inhibit cancer growth. |
| 3935- | RT, | Sodium rutin ameliorates Alzheimer's disease-like pathology by enhancing microglial amyloid-β clearance |
| - | in-vivo, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:143 Target#:230 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid